A Phase 1/2 interventional study of ECT-001 (UM171) expanded cord blood in Multiple Myeloma, sponsored by Ciusss de L'Est de l'Île de Montréal. Completed at 1 site in Canada. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-03-18.
Sponsored by Ciusss de L'Est de l'Île de Montréal · Phase 1/2, Interventional, and Treatment
Multiple Myeloma (MM) is a morbid disease associated with a poor outcome and while current therapies with new drugs have improved survival, MM still remains incurable in most patients. The only potential curative treatment remains allogeneic Hematopoietic stem cell transplant (HSCT), as shown by our cohort of 92 newly diagnosed patients who received a sibling tandem auto-allo (HSCT) with an estimated 10-year progression free survival (PFS) of 43%. However, the high incidences of toxicities including chronic graft-versus-host-disease (GVHD) (up to 79%) and disease progression (up to 49%) impair improvement in cure rate. Using umbilical cord blood (CB) as an alternative source of hematopoietic stem cells (HSC) could be superior biologically because of their increased proliferative capacity, greater number of progeny with longer telomeres and better anti-tumor efficacy in presence of positive residual disease. Moreover, using CB has been shown to decrease incidence of chronic GVHD. However, CBs have the disadvantage of having a limited HSC dose leading to prolonged cytopenia and higher risk of infections.
In a first in-human trial using CB expanded with the ECT-001 (UM171) molecule (clinicaltrial.gov # NCT02668315), the median net expansion of HSC was 36 fold, which allows for the selection of better HLA matched CB regardless of their lower HSC dose. Moreover, the ECT-001 expanded CBs have a different cell composition than regular CBs, with more than 25% of dendritic cell precursors. This, combined to better HLA matched CBs, may reduce chronic GVHD incidence and improve immune reconstitution. To date, 22 patients received an ECT-001 expanded CB and the procedure proved to be safe and feasible.
In this new trial, the goal is to evaluate the safety and efficacy of ECT-001 expanded CB transplant in high risk MM patients.
This is a single institution, prospective, phase I/II open-label study in a maximum of 20 patients evaluating a novel treatment strategy in NDMM patients with high-risk disease who do not have a 6/6 compatible sibling donor. Participating patients will be from Hôpital Maisonneuve-Rosemont (HMR) or referred to HMR for this protocol. Newly diagnosed multiple myeloma patients will be evaluated for eligibility before or during the autologous stem cell transplant (ASCT) period. After a Bortezomib-based induction treatment (VTD, CyBorD, RVD or PAD [in patients with plasma cell leukemia]) for a minimum of 4 cycles, followed by Melphalan ≥ 140 mg/m2 and ASCT, eligible patients who accept to participate will undergo screening evaluation to receive a Reduced Intensity (RIC) allogeneic HSCT with ECT-001 expanded CB. It is estimated that 18 months will be necessary to enroll the targeted sample size.
Once eligibility has been confirmed, study treatment will begin. After an ASCT, eligible patients will receive a conditioning regimen before receiving a RIC allogeneic HSCT with an ECT-001 expanded CB on day 0. Patients will be followed at least every week for the first 3 months, then every month, in the absence of GVHD, for disease evaluation and adverse events. Occurrence and severity of acute GVHD will be evaluated using the modified Glucksberg176 and IBMTR177 criteria, while chronic GVHD will be evaluated using the NIH178 criteria.
The trial will be terminated when all patients have been followed for 5 years after allogeneic HSCT.
Newly diagnosed multiple myeloma using the International Myeloma Working Group criteria with measurable disease and any of the following:
i. t(4;14), t(14;16), t(14;20), del(17p13), chromosome 1 abnormalities with ISS II or III; ii. Revised-ISS 3; iii. Primary plasma cell leukemia; iv. Refractory to first line triplet Bortezomib-based induction treatment. v. ≥ 2 cytogenetics abnormalities as defined above regardless of ISS stage
Exclusion Criteria:
1. Patients will receive a reduced intensity conditioning regimen containing Cyclophosphamide 50 mg/kg, Fludarabine 40 mg/m2 x 5 days and total body irradiation 200 cGy. 2. The cord to be expanded is thawed 7 days prior to transplant and undergoes CD34+ selection. The CD34+ product will be placed in the fed-batch culture with UM171 for a 7-day expansion and is infused fresh on Day 0. The CD34- product is cryopreserved and will be thawed and infused on Day +1. 3. Patients will receive standard supportive care and GVHD prophylaxis with Mycophenolate mofetil and Tacrolimus.
Biological: ECT-001 (UM171) expanded cord blood
ECT-001 expanded cord-blood will be produced and infused on site
Safety of ECT-001 expanded CB expansion as measured by toxicity evaluation
AEs with a CTCAE grade ≥ 3 (non hematologic) and with a grade ≥ 4 (hematologic) will be reported from the beginning of the conditioning regimen up to 5 years after CB transplant.
Time frame: 5 years
Feasibility of ECT-001 expanded CB expansion
Number of successful expansion and infusions in an outpatient nonmyeloablative transplant condition for high-risk myeloma patients
Time frame: 5 years
Measure of the kinetics of donor lymphoid cells recovery
Donor lymphocytes cells recovery assessed by chimerism analysis.
Time frame: 2 years
Measure of the kinetics of donor myeloid cells recovery
Time to neutrophils and platelets engraftment will be measured
Time frame: 2 years
Incidence of chronic GVHD by grade at 1 years by NIH criteria.
The incidence of chronic GVHD will be evaluated at 1 years using the recommendations of the NIH Consensus Conference and recently updated. Analysis by cumulative incidence
Time frame: 1 year
Incidence of chronic GVHD by grade at 2 years by NIH criteria.
The incidence of chronic GVHD will be evaluated at 1 years using the recommendations of the NIH Consensus Conference and recently updated. Analysis by cumulative incidence
Time frame: 2 years
Correlation between neutrophil and CD34+ doses infused
Regression analysis
Time frame: 2 years
Correlation between neutrophil and CD34+CD45RA+ doses infused
Regression analysis. Time to neutrophil and platelet engraftment will be correlated to the CD34+ and the CD34+CD45RA- dose (which includes all human hematopoietic stem cells (HSCs): long term and short term repopulating cells) contained in the expanded graft. Expansion and cultures might change the characteristics and behaviour of CD34+ cells, hence the need to look at the correlation between primitive CD34+CD45RA- subpopulation and engraftment.
Time frame: 2 years
Incidence of graft failure
Cumulative incidence of graft failure by type (primary or secondary). For Primary engraftment failure will be defined as non-achieving a T lymphocyte chimerism of ≥30% at D+28 and ≥70% at D+180. Secondary graft failure will be defined as followed : ANC drops below 0.5x109/L for 14 consecutive days, unresponsive to G-CSF without any identifiable cause (medication, viral infection, vitamin deficiency or other) or \<5% donor chimerism at any time point beyond initial engraftment in the absence of relapse and graft dominance by 2nd infused cord or other stem cell source.
Time frame: 2 years
Evaluation of T Cells reconstitution
Evaluation at several levels : * Multiparametric flow cytometry to quantify the proportion of naïve (CD45RA+/CD27+) and memory (CD45RA-/CD27+) cells. * TREC to measure thymic output * Diversity of the T cell repertoire (deep sequencing) * T-cell function (Elispot assays)
Time frame: 3 years
Evaluation of B cells reconstitution
B cell evaluation will be carried out prospectively using flow cytometry (CD19+), immunoglobulin (Ig) measurements, and PCR for donor B cell chimerism .
Time frame: 3 years
Evaluation of NK Cells reconstitution
NK cell evaluation will be performed by flow cytometry (CD 16+/56+) and chimerism analysis.
Time frame: 3 years
Evaluation of expanded HSC activity in vivo
Standard in vitro (long term culture-initiating cells and colony forming cells) and in vivo (the NSG mouse model) assays
Time frame: 3 years
Incidence of acute GVHD at day +120
Analysis by cumulative incidence
Time frame: 4 months
Incidence of acute GVHD at 6 month
Analysis by cumulative incidence
Time frame: 6 months
Incidence of acute GVHD at 1 year
Analysis by cumulative incidence
Time frame: 1 year
Incidence of grade >=3 infectious complications
Analysis by cumulative incidence
Time frame: 5 years
Incidence of engraftment syndrome requiring therapy
Analysis by cumulative incidence
Time frame: 2 years
Duration of hospitalization
Number of days of hospitalization during the first 180 days post-transplant
Time frame: 6 months
Non relapse mortality at day +120
Analysis by cumulative incidence
Time frame: 4 months
Non relapse mortality at 1 year
Analysis by cumulative incidence
Time frame: 1 year
Non relapse mortality at 2 year
Analysis by cumulative incidence
Time frame: 2 years
Progression free survival at 2 years
Kaplan Meier analysis
Time frame: 2 years
Overall survival at 2 years
Kaplan Meier analysis
Time frame: 2 years
Response to treatment at 1 year after allogeneic transplant
Evaluation of response categories according to the International Myeloma Working Group (IMWG)
Time frame: 1 years
Response to treatment at 2 year after allogeneic transplant
Evaluation of response categories according to the International Myeloma Working Group (IMWG)
Time frame: 2 years
Best response achieve at 1 year after allogeneic transplant
Evaluation of the best response during the 1 st year post-transplant
Time frame: 1 years
Best response achieve at 2 year after allogeneic transplant
Evaluation of the best response during the 2 years post-transplant
Time frame: 2 years
Minimal residual disease post transplant
Next Generation flow cytometry to determine how efficient an expanded CB is at reducing MM burden
Time frame: 5 years
Patient's quality of life
Assessment through Quality of Life questionnaires
Time frame: 5 years
Pharmaco-economic evaluation of the proposed treatment
Developement of an analysis model to determine if ECT-001 expanded CB to treat MM has a better cost-efficiency ratio than conventional chemotherapy-based treatment
Time frame: 5 years
Plan to share: No
This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Ciusss de L'Est de l'Île de Montréal